The NeoTYPE GIST/Soft Tissue Tumor Profile analyzes 43 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. A microsatellite instability (MSI) NGS result of “indeterminate” will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available.
NGS (38 genes + 2 biomarkers): AKT1, AKT2, AKT3, ARID1A, ATM, BRAF, CDKN2A, CTNNB1, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNAS, HRAS, KIT, KRAS, MAP2K1, MET, Microsatellite Instability (MSI), NF1, NRAS, NTRK1 fusions, NTRK2 fusions, NTRK3 fusions, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, SDHA, SDHB, SDHC, SDHD, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
FISH (2 FISH): MET, PTEN (tech-only available)
IHC (1 biomarker): PD-L1 LDT (tech-only available)
The GIST and Soft Tissue Tumor Profile characterizes primary or metastatic gastrointestinal stromal tumors, sarcomas, and other soft tissue primary or metastatic tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease, patients with an atypical clinical presentation, and patients with resistant disease to explore options in clinical trials.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.